Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Bristol Myers Squibb

Mass shooting in central business district shakes Manhattan, leaves at least 4 dead

345 Park Avenue hosts Blackstone, the world’s largest alternative asset manager, the NFL, KPMG, and Bristol Myers Squibb, among others.

Fortune

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Bristol-Myers Squibb Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.

Benzinga

DEI is emerging triumphant in shareholder battles across at companies ranging from Coca-Cola to Berkshire Hathaway

Here’s what happened to anti-DEI proposals put before shareholders at several U.S. companies, including Apple, Goldman Sachs, and Costco.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat

Bristol Myers Squibb stock reversed higher Thursday after the drugmaker beat first-quarter expectations and raised its outlook for the year.

Investors Business Daily

Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test

Shares of Bristol Myers Squibb tumbled Wednesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.

Investors Business Daily

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It

Bristol Myers Squibb stock skidded Tuesday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.

Investors Business Daily

Bristol Myers Stock: This Covered Call Could Enhance Your Return Beyond A 4% Dividend Yield

The sold call produces a 9.83% annualized yield in addition to the dividend.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Inside the futuristic biotech startup Cellares that’s building a cure for cancer with $355 million in funding

Why New Jersey is a hub for biotech manufacturing.

Fortune

Bristol Myers Squibb Shows Market Leadership With Jump To 93 RS Rating

Bristol Myers Squibb shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Stocks To Watch: Bristol Myers Squibb Sees Relative Strength Rating Jump To 85

Bristol Myers Squibb sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

People with blood cancer to benefit from innovative new treatment on the NHS

The type of Car T-cell therapy involves taking a patient’s T-cells and modifying them.

Evening Standard

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook

Bristol Myers walloped sales views Thursday, but Bristol Myers Squibb stock took a hit on a light outlook hamstrung by generic competition.

Investors Business Daily

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Barchart

Why This Dividend Stock Just Scored a Rare Upgrade

Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Bristol Myers Squibb Stock Earns 83 RS Rating

Bristol Myers Squibb sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

Bristol Myers Squibb Clears Key Benchmark, Hitting 80-Plus RS Rating

Bristol Myers Squibb shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

Investors Business Daily

Bristol Myers Squibb Gets RS Rating Upgrade

Bristol Myers Squibb shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Bristol Myers Squibb Trying To Close In On Key Technical Measure

Bristol Myers Squibb shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade

Bristol Myers Squibb shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Bristol Myers Screams To A Year-High After Walloping Profit Expectations

Bristol Myers Squibb walloped profit expectations in the September quarter, and Bristol Myers stock screamed to a year-high.

Investors Business Daily

Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

The Independent UK

New schizophrenia drug ‘could change the lives of millions of people’

The US Food and Drug Administration has approved Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb.

Medical Daily

Cobenfy Gets FDA Approval: New Drug Offers Novel Treatment Mechanism For Schizophrenia

The new drug Cobenfy promises to revolutionize treatment for schizophrenia with its novel mechanism, the first of its kind in decades.

Investors Business Daily

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?

Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.